Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD

Authors Cantor J, Ma S, Turino G

Received 19 May 2017

Accepted for publication 24 July 2017

Published 18 September 2017 Volume 2017:12 Pages 2747—2752


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell

Jerome Cantor,1 Shuren Ma,2 Gerard Turino2

1Department of Pharmaceutical Sciences, St John’s University, 2Department of Medicine, St Luke’s Mount Sinai Hospital Center, New York, NY, USA

Abstract: A novel therapy for COPD involving the use of aerosolized hyaluronan (HA) was tested on a small cohort of COPD patients to determine both its safety and efficacy in reducing levels of desmosine and isodesmosine (DID), biomarkers for elastin degradation. In a 2-week, randomized, double-blind trial, 8 patients receiving 150 kDa HA (mean molecular weight) and 3 others given placebo did not show significant adverse effects with regard to spirometry, electrocardiograms, and hematological indices. Furthermore, measurements of DID in plasma from HA-treated patients indicated a progressive decrease over a 3-week period following initiation of treatment (r=−0.98; p=0.02), whereas patients receiving placebo showed no reduction in DID (r=−0.70; p=0.30). Measurements of sputum in the HA-treated group also revealed a progressive decrease in DID (r=−0.97; p=0.03), but this finding was limited by the absence of similar measurements in the placebo group. Nevertheless, the results of this small, pilot study support a longer-term trial of HA in a larger population of COPD patients.

Keywords: hyaluronan, COPD, desmosine, elastin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]